Welcome to our dedicated page for Medicus Pharma news (Ticker: MDCX), a resource for investors and traders seeking the latest updates and insights on Medicus Pharma stock.
Medicus Pharma Ltd. (NASDAQ: MDCX) is a biotech and life sciences company whose news flow centers on clinical trial progress, regulatory milestones, strategic collaborations and capital markets activity. The company describes itself as a precision guided biotech/life sciences organization focused on advancing SkinJect™, an investigational microneedle therapy for basal cell carcinoma (BCC) of the skin, and Teverelix, a long-acting GnRH antagonist for hormone-driven conditions.
News updates frequently cover the SkinJect™ program, including Phase 2 study SKNJCT-003 in the United States, regulatory and ethics approvals to expand into the United Kingdom, and SKNJCT-004 in the United Arab Emirates. Releases also highlight interactions with the U.S. Food and Drug Administration (FDA), such as Type C meeting feedback supporting a 505(b)(2) regulatory pathway and the filing of an FDA Commissioner’s National Priority Voucher (CNPV) application for SKNJCT-003.
Another major theme in MDCX news is the Teverelix pipeline, added through the acquisition of Antev Limited. Company communications describe prior Phase 1 and Phase 2a data, FDA guidance on Phase 3 design, and plans to use AI-enabled analytics—via an engagement with Reliant AI Inc.—to support upcoming Teverelix clinical studies. Additional coverage includes Phase 1 data in healthy female volunteers and acceptance of Teverelix research for presentation at a leading endocrinology conference.
Investors following MDCX news will also see announcements on collaborations, such as the Gorlin Syndrome Alliance partnership for compassionate access to SkinJect™ and a non-binding memorandum of understanding with Helix Nanotechnologies, Inc. around thermostable infectious disease vaccines. Capital markets updates, including warrant inducement agreements, standby equity purchase activity and debenture financings, are disclosed through press releases and Form 8-K filings.
This news page aggregates these developments so readers can review Medicus Pharma’s clinical, regulatory, partnering and financing announcements in one place.
Medicus Pharma Ltd. (NASDAQ: MDCX) announced the voting results from its Annual and Special Meeting held on July 22, 2025. The company notably welcomed two high-profile additions to its Board of Directors: former Congresswoman Cathy McMorris Rodgers, the first female Chair of the House Committee on Energy & Commerce, and Ajay Raju, a prominent attorney and venture capitalist who previously invested $8M in the company's pre-IPO round.
All eight board nominees were elected with overwhelming support, each receiving over 99.8% of votes. Shareholders also approved key measures including the appointment of KPMG LLP as auditors, amendments to company bylaws regarding shareholder meeting quorum requirements, and approval of a Standby Equity Purchase Agreement with YA II PN, Ltd.
Medicus Pharma Ltd. (NASDAQ: MDCX) announced its participation in the BTIG Virtual Biotech Conference 2025, with CEO Dr. Raza Bokhari scheduled for a Fireside Chat on July 30, 2025, at 9:20 a.m. ET.
The company provided updates on its lead asset, SkinJect Inc., which is developing a novel treatment for non-melanoma skin cancer using D-MNA technology. Their Phase 2 study (SKNJCT-003) showed promising interim results with over 60% clinical clearance. The trial has been expanded to 90 subjects and additional European sites. A parallel study (SKNJCT-004) is ongoing in the UAE with 36 patients across four sites.
Additionally, Medicus announced a definitive agreement to acquire Antev Ltd., a UK biotech company developing Teverelix for prostate cancer treatment, with the deal expected to close by August 2025.
Medicus Pharma (NASDAQ: MDCX) has submitted a Type C meeting request to the FDA for October 2025 to discuss their D-MNA (Dissolvable Doxorubicin-containing Microneedle Arrays) development program for treating Basal Cell Carcinoma (BCC).
The company's Phase 2 clinical trial SKNJCT-003 is currently ongoing at 9 U.S. sites, with an expanded enrollment to 90 subjects. A March 2025 interim analysis showed promising results with over 60% clinical clearance. The trial evaluates two dose levels (100μg and 200μg) against a placebo control.
Additionally, Medicus is conducting the SKNJCT-004 trial in the UAE across four sites, targeting 36 patients. In June 2025, the company announced a definitive agreement to acquire Antev Limited, a UK biotech developing Teverelix for prostate cancer treatment.
Medicus Pharma (NASDAQ: MDCX) has announced a definitive agreement to acquire Antev Ltd., a UK-based clinical-stage drug development company. Under the agreement, Antev shareholders will receive a 17% equity stake in Medicus (2,666,600 shares) plus up to $65 million in contingent payments tied to FDA Phase 2 and New Drug Application approvals.
The acquisition centers on Antev's development of Teverelix, a next-generation GnRH antagonist, targeting two key indications: acute urinary retention (AUR) and advanced prostate cancer in cardiovascular high-risk patients. For AUR, Teverelix aims to be first-in-class with a $2B+ annual market opportunity, targeting nearly 1 million annual AUR episodes in the US. The FDA-approved Phase 2b study will involve 390 men across 60-70 US and EU sites.
For advanced prostate cancer, Teverelix targets a $4B+ annual market, specifically focusing on 300,000-500,000 US patients with increased cardiovascular risk. The FDA-approved Phase 2b open-label study will recruit 40 men to evaluate Teverelix as potentially the first hormone therapy specifically labeled for prostate cancer patients with cardiovascular disease history.
The transaction is expected to close by August 2025, subject to Antev shareholder approval and other regulatory requirements. The deal includes a 9-month staggered lock-up period and 36-month voting rights agreement favoring Medicus management.
Medicus Pharma Ltd (NASDAQ: MDCX) has received approval from the UAE Department of Health to begin a Phase 2 clinical study (SKNJCT-004) for treating Basal Cell Carcinoma (BCC) of the skin. The study will involve 36 patients across four UAE medical centers, including Cleveland Clinic Abu Dhabi.
The randomized, double-blind trial will evaluate two dose levels of D-MNA (100μg and 200μg) against a placebo. This follows successful Phase 1 results from March 2021, where the treatment showed safety and tolerability with 6 participants achieving complete responses. The company is also conducting a Phase 2 study (SKNJCT-003) in the US, which showed positive interim results with over 60% clinical clearance.
Additionally, Medicus recently announced plans to acquire Antev Ltd., a UK biotech company developing Teverelix for prostate cancer and urinary retention treatment.